← Leaderboards
Ranjit Bindra
Yale University
$5,884,099
Attributed
$8,468,273
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,026,191 · 8
By mechanism
U19$8,836,656 · 3
R01$6,562,410 · 3
R21$460,625 · 1
R03$166,500 · 1
Top collaborators
- Evanthia Galanis7 shared
- Jann N Sarkaria7 shared
- Stephanie Halene6 shared
- Antonio M Omuro4 shared
- Seth B. Herzon3 shared
- W Mark Saltzman2 shared
Most similar at Yale University
Same institution · by research overlap
- Alan Clayton Sartorelli$9,274,853
- Seth B. Herzon$10,471,068
- Chima Ndumele$3,917,339
- Amanda Ruth Quijano$50,955
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseDna DamageChemotherapyRadiation TherapyClinicTranslatingIn VivoInhibitorTemozolomideBrain NeoplasmsNovel Therapeutic InterventionPharmaceutical PreparationsDefectOperative Surgical ProceduresPathway InteractionsGlioblastomaMalignant NeoplasmsGliomaIn VitroDna RepairFda ApprovedClinical TrialsNeoplastic Cell
Grant awards (30)
Center of Innovation for Brain Tumor Therapeutics$1,203,578
U19 · FY2025 · CA
Novel therapeutics for the targeted eradication of DDR-defective tumors$654,163
R01 · FY2025 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$585,107
R01 · FY2025 · CA · contact PI
Novel DNA damage response inhibitor and alkylator combinations for GBM$158,033
U19 · FY2025 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,861,663
U19 · FY2024 · CA
Novel therapeutics for the targeted eradication of DDR-defective tumors$621,455
R01 · FY2024 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$555,851
R01 · FY2024 · CA · contact PI
Novel DNA damage response inhibitor and alkylator combinations for GBM$324,910
U19 · FY2024 · CA · contact PI
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$223,251
R01 · FY2024 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,999,213
U19 · FY2023 · CA
Novel therapeutics for the targeted eradication of DDR-defective tumors$654,163
R01 · FY2023 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$573,404
R01 · FY2023 · CA · contact PI
Novel DNA damage response inhibitor and alkylator combinations for GBM$278,878
U19 · FY2023 · CA · contact PI
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$162,244
R01 · FY2023 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,187,659
U19 · FY2022 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$585,106
R01 · FY2022 · CA · contact PI
Novel DNA damage response inhibitor and alkylator combinations for GBM$244,688
U19 · FY2022 · CA · contact PI
Admin-Core-001$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics - Diversity Supplement$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics$1,243,819
U19 · FY2021 · CA
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer$385,106
R01 · FY2021 · CA · contact PI
Novel DNA damage response inhibitor and alkylator combinations for GBM$210,243
U19 · FY2021 · CA · contact PI
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer$392,615
R01 · FY2020 · CA · contact PI
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer$374,228
R01 · FY2019 · CA · contact PI
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer$393,538
R01 · FY2018 · CA · contact PI
Drug delivery system for enhancing radiation therapy in pediatric glioma$209,375
R21 · FY2018 · HD
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in Cancer$402,179
R01 · FY2017 · CA · contact PI
Drug delivery system for enhancing radiation therapy in pediatric glioma$251,250
R21 · FY2017 · HD
Development of a Novel Assay to Measure DSB Repair at Endogenous Loci in Cells$83,250
R03 · FY2016 · CA · contact PI
Development of a Novel Assay to Measure DSB Repair at Endogenous Loci in Cells$83,250
R03 · FY2015 · CA · contact PI